Heart failure studies succeed when sites can quickly identify and engage eligible patients within complex care pathways. Drawing on more than 30 years of cardiovascular experience, Worldwide has enrolled 8,900+ patients across 1,000+ global sites in HFrEF, HFpEF, acute and decompensated heart failure programs. Our teams know how to manage hospitalization-driven enrollment, event-based endpoints, adjudication, and complex cardio-kidney-metabolic populations.
We’ll connect you with the right Cardiovascular clinical development team
Why Heart Failure Programs Demand Specialized Support
Worldwide brings together sites selected for patient access and strong referral pathways, endpoint and adjudication infrastructure built for outcomes trials, and cardiovascular leaders who stay with the program from start to finish. This helps sponsors reduce execution risk, protect data quality and reach key development decisions on time.
HFrEF, HFpEF, acute, chronic, and hospitalized heart failure populations each call for different enrollment strategies, endpoint expertise, and site capabilities. Worldwide builds study-specific site networks based on patient pathways, referral patterns and phenotype-specific experience to maximize enrollment efficiency and data quality.
Comorbidities, hospitalizations and caregiver dependence can make it hard for heart failure patients to stay in long-term studies. Worldwide plans for retention from protocol design onward. That includes patient-centric visit schedules, burden reduction, caregiver support planning, and proactive engagement that keep patients in the study and protect endpoint integrity.
Large heart failure outcomes studies require robust endpoint management, event adjudication, and long-term operational oversight. Worldwide brings the infrastructure and cardiovascular expertise to manage high event volumes across complex, multi-country programs while maintaining endpoint quality and delivering reliable outcomes data.

Partnership & Approach
Sponsors work with the same senior scientific, medical, and operational leaders from bid defense through database lock, providing continuity, accountability, and rapid decision-making throughout the program. Combined with decades of heart failure trial experience, this partnership model helps sponsors navigate complexity and maintain momentum across the entire development lifecycle.
A proven record of delivering heart failure studies across the full spectrum of disease, from early development through global outcomes trials. Worldwide brings the scientific expertise, operational infrastructure, and cardiovascular leadership needed to keep complex programs moving forward and support the development decisions sponsors plan around.
Patients
Sites
Heart failure delivery spanning HFrEF, HFpEF, acute, chronic, and decompensated populations from Phase I-IV.

Patients
Sites
Countries
A global Phase III program in heart failure and type 2 diabetes delivered full service across North America and Europe.

Patients
Sites
Countries
A Phase IV acute heart failure program delivered full service, spanning Western Europe, Eastern Europe, the Middle East, Latin America, and Asia Pacific.

Why Worldwide for Heart Failure Trials
Sites are selected based on the care pathways, referral patterns, and patient flow specific to the heart failure population under study. National cardiovascular leaders drive country-level activation strategies, helping sponsors improve patient identification, accelerate enrollment, and reduce startup risk.
A no-backlog approach to data management keeps clinical and endpoint data current throughout long-duration heart failure studies. By combining continuous review, timely query resolution, and disciplined endpoint oversight, Worldwide helps preserve data quality, accelerate database lock, and reduce the risk of delays at top-line analysis.
A dedicated cardiovascular organization of 400+ professionals, 60+ experienced project managers, and 14 dedicated medical monitors provides the continuity, expertise, and operational leadership needed to support complex heart failure programs from study startup through final delivery.
Frequently Asked Questions
We’ve addressed the most common sponsor questions about heart failure trial design and execution. If you don’t see what you’re looking for, connect with our cardiovascular team for a tailored discussion.
HFpEF clinical development has distinct challenges compared with HFrEF, requiring enrollment strategies, endpoint planning, and site selection tailored to a different patient population. Because HFpEF patients are typically older and managed across specialties, recruitment depends on experienced HFpEF sites selected for phenotype-specific patient access, investigator expertise, imaging capabilities, and complex cardiovascular population management. Background therapy also shapes eligibility, event rates, endpoints, and study design. Worldwide helps sponsors navigate these complexities while maintaining focus on enrollment efficiency, data quality, and regulatory expectations.
Acute heart failure programs depend on sites with the infrastructure, patient flow, and expertise to identify and enroll patients within narrow hospitalization-based enrollment windows. Worldwide has delivered acute heart failure studies across 146 sites in 13 countries and supported global outcomes trials spanning Europe, the Middle East, Latin America, and Asia-Pacific, bringing experience in site selection, rapid enrollment, event management, and study execution through database lock.
Site selection starts with understanding how heart failure patients are identified, referred, and treated within each healthcare system. Worldwide evaluates sites based on patient pathway visibility, investigator expertise, historical performance, and access to the specific heart failure population under study, while cardiovascular leaders drive country-level activation strategies to improve enrollment efficiency and reduce risk.
Retention is built into study design from the outset. Worldwide evaluates visit burden, travel requirements, caregiver involvement, and patient care pathways before enrollment begins, then supports ongoing engagement through proactive communication and patient-centered retention strategies. This approach helps reduce attrition, protect endpoint integrity, and maintain study continuity throughout long-duration heart failure trials.
Worldwide has delivered heart failure programs across HFrEF, HFpEF, acute and chronic heart failure, hospitalized decompensated HF, and cardiometabolic subpopulations including HF with T2D, CKD, and iron deficiency. With experience spanning Phase I-IV, site selection and feasibility strategies are tailored to the unique patient pathways, endpoint requirements, and operational demands of each heart failure population.
Worldwide manages large heart failure outcomes programs through coordinated endpoint adjudication, central laboratory oversight, medical review, and no-backlog data management practices. By keeping event documentation and data review current throughout the study, we help preserve endpoint integrity, reduce database lock risk, and support timely delivery of top-line results for complex global cardiovascular trials.
Successful global heart failure programs require country-specific strategies that account for differences in healthcare systems, regulatory environments, and patient access patterns. Worldwide combines global cardiovascular infrastructure with local operational leadership, enabling national and regional experts to drive site activation, investigator engagement, enrollment, and retention within each participating country. Our teams coordinate regulatory, operational, and recruitment activities across regions while maintaining consistent study oversight and data quality. Central laboratory and endpoint strategies are supported by contingency planning to ensure continuity throughout the program lifecycle. We apply this approach across multinational heart failure outcomes studies spanning Western and Eastern Europe, the Middle East, Latin America, and Asia-Pacific.
Yes. Worldwide supports heart failure development across the full clinical lifecycle, from first-in-human and early proof-of-concept studies through large-scale Phase III outcomes trials and Phase IV post-marketing research. Worldwide has supported early phase heart failure development, including a Phase Ib/IIa HFrEF study conducted across Sweden, the U.K., the Netherlands, and Italy, with full DSMB oversight, while also delivering large multinational outcomes programs involving complex endpoint adjudication, long-term follow-up, and extensive global site networks. This breadth of experience allows sponsors to work with a single cardiovascular partner as programs evolve, maintaining continuity of scientific leadership, operational expertise, and investigator relationships from start to finish.
Worldwide applies a proactive oversight model that continuously evaluates recruitment performance, retention trends, site productivity, endpoint activity, and data quality signals at both the site and country level. Potential challenges such as shifts in referral patterns, enrollment slowdowns, patient retention risks, or laboratory and data management issues are identified and addressed before the affect study milestones. Senior scientific, medical, and operational leaders remain actively engaged throughout the program, enabling rapid decision-making and targeted mitigation strategies when issues emerge.